Roche Holding expects sales and core earnings to keep growing this year after beating analysts' expectations for 2024. The Swiss pharmaceutical giant is forecasting sales growth in the ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Ontruzant, the first biosimilar version of Roche’s Herceptin (trastuzumab ... and is indicated for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.

The PD-1 checkpoint inhibitor cancer treatment is fast becoming the backbone ... biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.

Dr Rebecca Dobson discussed the acute need to assess cardiovascular risk in cancer care, cardiotoxicity and the MDT in cardio ...